This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
In recent years, ophthalmologists have grown accustomed to clinical trials that demonstrate therapeutic benefit. The first major eye trial in recent years was the Diabetic Retinopathy Study,1 which reported in 1976 that scatter laser photocoagulation was effective in reducing the risk of loss of vision in eyes with proliferative retinopathy. In 1982, the Macular Photocoagulation Study (MPS) Group2 announced that prompt argon laser photocoagulation of neovascular membranes (NVMs) outside the foveal avascular zone (FAZ) reduced the risk of severe loss of vision in patients with age-related macular degeneration (AMD).
See also p 1299.
In 1983, the MPS Group3 reported similar findings for treatment of eyes with ocular histoplasmosis and new vessels outside the FAZ. Also in 1983, the Proliferative Sickle Cell Retinopathy Trial4 reported that feeder vessel photocoagulation reduced the incidence of vitreous hemorrhage and subsequent loss of vision, and the Central Serous Chorioretinopathy Trial5
Fine SL. Clinical Trials and the Practice of Ophthalmology. Arch Ophthalmol. 1984;102(9):1282-1285. doi:10.1001/archopht.1984.01040031032018